Industry Reports

Patent Research and Operational Guide for Daiichi Sankyo's ADC Drug DS-8201(2)

30 August 2024
4 min read

Based on the characteristics of ADC drugs, we have summarized the process for conducting patent research on ADC drugs.You can start by reading the following article to get background information.

Patent Research and Operational Guide for Daiichi Sankyo's ADC Drug DS-8201(1)

 

DS-8201, also known as fam-trastuzumab deruxtecan-nxki (Enhertu), was officially approved for market by the U.S. Food and Drug Administration (FDA) in December 2019 and by the China's National Medical Products Administration (NMPA) in February 2023. This novel HER2-targeting ADC is effective not only against tumors with high HER2 expression that respond to trastuzumab, but also shows good efficacy against tumors with low HER2 expression where trastuzumab is ineffective. Additionally, it can treat brain metastases from tumors and has significant clinical application value in HER2-negative breast cancer, HER2-positive breast cancer, HER2-expressing gastric adenocarcinoma, and metastatic non-small cell lung cancer. 

As Daiichi Sankyo's flagship product, DS-8201's global sales in the first quarter of 2024 reached $879 million, an increase of $348 million compared to the same period in 2023. This patent research guide focuses on DS-8201 and includes the most recent data as of April 28, 2024.

Retrieval of Basic Information on DS-8201

First, log in to Patsnap Synapse and search for "DS-8201" from the homepage. Next, click on the retrieved DS-8201 drug card and navigate to the ‘Overview’ tab.

图形用户界面, 应用程序, Teams

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The compilation of basic information regarding DS-8201

表格

描述已自动生成

文本

低可信度描述已自动生成

Initial Patent Search and Core Patent Identification for DS-8201 in Patsnap Synapse

From the DS-8201 page, select the "Patent" tab and click "View All Patents" on the right to retrieve all the patents related to DS-8201. 

Next, select the resulting 26 simple families and add them to a new Workspace. Based on Synapse’s manual indexing, the following can be preliminarily deduced as being core product patent families: patent application CN104755494A, titled "Antibody-Drug Conjugate", patent application WO2014061277A1, titled "Antibody-drug conjugate produced by binding through linker having hydrophilic structure", patent application JP5998289B2, titled "Anti-HER2 antibody-drug conjugate", and patent application US20170035906A1, titled "(Anti-HER2 Antibody)-Drug Conjugate". The above patent families are classified as Sequence, Formulation, and New Use patent types. Thus, it is preliminarily determined that the above four patent families are core product patents. Subsequently, CN104755494A WO2014061277A1, CN105829346B (simple family patent of JP5998289B2), and US11185594B2 (authorized versions of US20170035906A1) are selected for further analysis.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序

描述已自动生成

Analysis of Core Product Patents to Ascertain the Structure of DS-8201

Next, launch Patsnap Analytics by clicking on ‘View in Analytics’ to perform an in-depth analysis of each core product patent family. Then, open the patent details for CN105531288A. 

Upon examination, it is initially determined that the core substance patent CN105531288A (Anti-PD1 antibodies and their use as therapeutics and diagnostics) comprises 67 simple family members and has been cited 39 times. This patent outlines antibodies that specifically target PD-1, impeding the cell signal transduction and activity mediated by PD1 in immune cells. It also defines a set of amino acid residues necessary for binding PD1 ligands and describes the application of these antibodies in treating or diagnosing cancers, infectious diseases, or other pathological conditions regulated by PD1-mediated functions. 

From this assessment, it is evident that the core substance patent safeguards multiple antibody sequence CDRs. However, it does not explicitly specify the CDR sequences.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

图形用户界面, 文本

描述已自动生成

By reading the claims of CN104755494B, WO2014061277A1, CN105829346B, and US11185594B2, we find that the linker structure described in the claims of WO2014061277A1 and US11185594B2 is different from that described in the claims of CN104755494B and CN105829346B. Through cross-validation with the relevant information summarized in section 2.2 and publicly available information retrieved online, we confirm that the structures protected in the claims of CN104755494B and CN105829346B match DS-8201, as illustrated in Figure 2.4.2. The linker structure described in the claims of WO2014061277A1 and US11185594B2 corresponds to other structures in the same series. Furthermore, we find that the claims of CN105829346B include specific toxin compound structures, linker structures, and information on the antibody heavy and light chains. Therefore, CN105829346B is further analyzed as the core product patent.

图示

描述已自动生成

The original patents for the three components of DS-8201 were not found among the 26 simple patent families. To locate the original development history of each component, the next section of this guide will analyze the original patents of each component in section 2.5 of this report through a structure and sequence search.

For more information, you can click the following article link

Patent Research and Operational Guide for Daiichi Sankyo's ADC Drug DS-8201(3)

For more information, please click the image link below to access the full report.

图形用户界面, 网站

描述已自动生成

Zai Lab Presents ZL-1218 Phase 1 Results at ESMO 2024: Advancing Anti-CCR8 Therapy in Tumors
Latest Hotspot
3 min read
Zai Lab Presents ZL-1218 Phase 1 Results at ESMO 2024: Advancing Anti-CCR8 Therapy in Tumors
30 August 2024
Zai Lab to Share Early Findings from Phase 1 Study of ZL-1218, a Potential Anti-CCR8 Antibody for Advanced Tumor Therapy, at ESMO Congress 2024.
Read →
Patent Research and Operational Guide for Daiichi Sankyo's ADC Drug DS-8201(1)
Patent Research and Operational Guide for Daiichi Sankyo's ADC Drug DS-8201(1)
30 August 2024
Currently, 272 ADC drugs have been initiated for clinical trials globally. Excluding the market withdrawal of Belantamab mafodotin (Blenrep®), 14 approved ADC products remain available.
Read →
EU Commission Approves RYBREVANT® (Amivantamab) with Chemotherapy for Treatment-Resistant Advanced EGFR-Mutated NSCLC in Adults
Latest Hotspot
4 min read
EU Commission Approves RYBREVANT® (Amivantamab) with Chemotherapy for Treatment-Resistant Advanced EGFR-Mutated NSCLC in Adults
30 August 2024
The European Commission greenlights RYBREVANT®▼ (amivantamab) alongside chemotherapy for adults with advanced EGFR-mutated NSCLC after previous treatments haven't worked.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 30
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 30
30 August 2024
Aug 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.